Edition:
India

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

2.61USD
2:09am IST
Change (% chg)

$-0.04 (-1.51%)
Prev Close
$2.65
Open
$2.69
Day's High
$2.69
Day's Low
$2.61
Volume
26,993
Avg. Vol
587,495
52-wk High
$8.68
52-wk Low
$1.25

Select another date:

Thu, Jan 4 2018

BRIEF-Celsion Announces FDA Clearance Of The OVATION II Study For The Evaluation Of GEN-1 Immunotherapy

* CELSION ANNOUNCES FDA CLEARANCE OF THE OVATION II STUDY FOR THE EVALUATION OF GEN-1 IMMUNOTHERAPY TO TREAT NEWLY DIAGNOSED STAGE III/IV OVARIAN CANCER

BRIEF-Celsion reports Q3 loss of $0.70/shr

* Celsion Corporation reports third quarter 2017 financial results and provides business update

BRIEF-Celsion files immunotherapy clinical protocol for the evaluation of Gen-1

* Celsion files immunotherapy clinical protocol for the evaluation of Gen-1 to treat newly diagnosed ovarian cancer

BRIEF-CELSION ANNOUNCES PRICING OF COMMON STOCK OFFERING

* CELSION CORPORATION ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS TO PURCHASE COMMON STOCK

BRIEF-Celsion provides update on Thermodox in liver cancer study

* Celsion provides update on Thermodox® in the Phase III Optima study of primary liver cancer

BRIEF-Celsion Corp Q2 loss per share $0.79

* Celsion corporation reports second quarter 2017 financial results and provides business update

BRIEF-Celsion Corp says DMC completes mid-study review of phase III thermodox optima study

* Data monitoring committee completes mid-study review of Celsion's phase III thermodox optima study in primary liver cancer

BRIEF-Celsion Corporation to delist from Tel Aviv stock exchange

* Celsion Corporation to delist from Tel Aviv stock exchange Source text for Eikon: Further company coverage:

BRIEF-Celsion Corp announces data from ovation study

* Celsion corp - ‍announces latest translational data from ovation study in newly diagnosed advanced ovarian cancer patients​ Source text for Eikon: Further company coverage:

Select another date: